Cytokines and T-Cell Homeostasis in HIV Infection

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S51-S57

  Freeman, Michael L ^a   Shive, Carey L ^b   Nguyen, Thao P ^a   Younes, Souheil Antoine ^a   Panigrahi, Soumya ^a   Lederman, Michael M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cytokines; HIV; T cells

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 5; INTERLEUKIN 7; TUMOR NECROSIS FACTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREACTIVITY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY;

ANIMALS; CYTOKINES; HIV INFECTIONS; HOMEOSTASIS; HUMANS; T-LYMPHOCYTES;

EID: 84990943459     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw287     Document Type: Article

References (50)

1. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719-33.
2. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
3. Funderburg NT, Andrade A, Chan ES, et al. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naive patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One 2013; 8:e83514.
4. Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis 2015; 60:1842-51.
5. Kelesidis T, Tran TT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis 2015; 61:651-60.
6. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
7. Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol 2009; 130:27-33.
8. Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 1990; 75:1305-10.
9. Aoyagi T, Matsui T. The cardiomyocyte as a source of cytokines in cardiac injury. J Cell Sci Ther 2012; S5:3.
10. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8 (suppl 2):S3.
11. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80.
12. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1-10.
13. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54.
14. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15:43-58.
15. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813:878-88.
16. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 2003; 73:713-21.
17. Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014; 40:40-50.
18. Jacoby JJ, Kalinowski A, Liu MG, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 2003; 100: 12929-34.
19. Zhang XL, Topley N, Ito T, Phillips A. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem 2005; 280:12239-45.
20. Luckett-Chastain LR, Gallucci RM. Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficient mice. Br J Dermatol 2009; 161:237-48.
21. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
22. Estes JD, Wietgrefe S, Schacker T, et al. Simian immunodeficiency virusinduced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007; 195:551-61.
23. Schacker TW, Brenchley JM, Beilman GJ, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13:556-60.
24. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol 1997; 158:5791-6.
25. Rochman I, Paul WE, Ben-Sasson SZ. IL-6 increases primed cell expansion and survival. J Immunol 2005; 174:4761-7.
26. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-8.
27. Curnow SJ, Scheel-Toellner D, JenkinsonW, et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 2004; 173:5290-7.
28. Oritani K, Tomiyama Y, Kincade PW, et al. Both Stat3-activation and Stat3-independent BCL2 downregulation are important for interleukin-6-induced apoptosis of 1A9-M cells. Blood 1999; 93:1346-54.
29. Lotz M, Jirik F, Kabouridis P, et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988; 167:1253-8.
30. Shive CL, Mudd JC, Funderburg NT, et al. Inflammatory cytokines drive CD4+ Tcell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. J Infect Dis 2014; 210:619-29.
31. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
32. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228-38.
33. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204:1217-26.
34. Shive CL, Clagett B, McCausland MR, et al. Inflammation perturbs the IL-7 axis, promoting senescence and exhaustion that broadly characterize immune failure in treated HIV infection. J Acquir Immune Defic Syndr 2016; 71:483-92.
35. David D, Keller H, Nait-Ighil L, et al. Involvement of Bcl-2 and IL-2R in HIVpositive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy. AIDS 2002; 16:1093-101.
36. Poli G, Bressler P, Kinter A, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990; 172:151-8.
37. Colle JH, Moreau JL, Fontanet A, et al. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients-effects of antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 42:277-85.
38. Colle JH, Moreau JL, Fontanet A, Lambotte O, Delfraissy JF, Theze J. The correlation between levels of IL-7Ralpha expression and responsiveness to IL-7 is lost in CD4 lymphocytes from HIV-infected patients. AIDS 2007; 21:101-3.
39. Lynch HE, Goldberg GL, Chidgey A, et al. Thymic involution and immune reconstitution. Trends Immunol 2009; 30:366-73.
40. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7:454-65.
41. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
42. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27:229-65.
43. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2:108-15.
44. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10:89-102.
45. Lukens JR, Gross JM, Kanneganti TD. IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol 2012; 3:315.
46. Reddy MM, Grieco MH. Neopterin and alpha and beta interleukin-1 levels in sera of patients with human immunodeficiency virus infection. J Clin Microbiol 1989; 27:1919-23.
47. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol 1997; 109:54-8.
48. Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis 2015; 211:19-27.
49. Larsson EL, Iscove NN, Coutinho A. Two distinct factors are required for induction of T-cell growth. Nature 1980; 283:664-6.
50. Smith KA, Lachman LB, Oppenheim JJ, Favata MF. The functional relationship of the interleukins. J Exp Med 1980; 151:1551-6. 51-178. These references are available in the Supplementary Appendix.